AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 271 min read$CXDO

CXDO Q3'26 Earnings: revenue estimate is 25.18M USD

Crexendo (CXDO) will report Q3'26 earnings on November 3, with expected revenue of 25.18M USD and EPS of 0.09 USD. Results will be released after market close at 4:00 PM ET.

Original reporting
tradingview.com
Published Oct 27, 2026, 11:01 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 27, 2026, 11:07 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
CXDO Q3'26 Earnings: revenue estimate is 25.18M USD — source image
Source · tradingview.com
Decision brief

The 30-second read

$CXDONeutralMed
01

Why it matters

The earnings estimate sets market expectations; any deviation could trigger volatility in a thinly traded stock.

02

Market read

First disclosure of Q3'26 guidance for CXDO; relevant for traders monitoring micro‑cap biotech earnings.

03

What to watch

Potential upcoming clinical trial updates or partnership news not disclosed in this brief could materially affect price.

Relevance 6/10Novelty 7/10Timing: pre‑market on Nov 3

Background

Crexendo is a small biotech focused on drug development platforms; its earnings are closely watched by niche investors.

Company-level read

Ticker impact

$CXDONeutralMedium confidence
Context

Crexendo, Inc. (CXDO) will release its Q3'26 earnings on Nov 3 with revenue estimated at $25.18M and EPS $0.09.

Expected impact

potential modest upside if results beat the modest estimate, or pressure if they miss.

Evidence & confidence

New guidance is the first public disclosure; market reaction will hinge on beat/miss relative to the low baseline.

Market effects

Sector

Provides a data point for the biotech sector's upcoming earnings season.

Regional

Limited to US micro‑cap investors.

Global

Low; impact confined to CXDO shareholders.

Counterpoint

What could challenge this read

Given the small size and modest guidance, the stock may be over‑reacting to any beat, presenting a short opportunity.

Key entities

  • Company
    Crexendo, Inc.

    Biotech firm reporting Q3'26 results.

Read at source← All news

Related articles

AUG 4
$CXDOMed

Crexendo Announces Strong Second Quarter 2026 Results

Crexendo, Inc. (CXDO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Crexendo Announces Strong Second Quarter 2026 Results PHOENIX, AZ / ACCESSWIRE / August 4, 2026 / Crexendo, Inc. (NASDAQ: CXDO), an award-winning software technology company that is a premier provider of cloud communication platform software and unified communication

SEC EDGAR 8-K6 min
MAY 30
$PAYMed

10 Best Growth Stocks to Buy with Low P/E Ratios

The article screens for growth stocks with average revenue growth of at least 30% over five years and forward P/E below 25, then ranks them by forward P/E. It highlights Paymentus (PAY) with forward P/E 22.92 and 31.72% revenue growth; Wedbush raised its target to $36 and Baird to $34 after strong Q1 results and raised 2026 guidance. It also cites Crexendo (CXDO) with forward P/E 18.73 and 32.99% growth; Needham raised its target to $12 after strong Q1 organic telecom growth and deal wins.

insidermonkey.com6 min
OCT 28
$DMCHighAI 9/10

Why is DMC Global stock surging today?

DMC Global (BOOM) stock rose 16% in pre-market trading after reporting Q3 earnings that exceeded estimates, with EPS of $0.48 vs. $0.11 consensus and revenue of $172.8M vs. $161.1M. Adjusted EBITDA increased 59% YoY to $13.6M, and net debt fell to $13.7M. Management guided Q4 revenue between $154M-$164M, roughly in line with analyst expectations. The company cited strong performance in its Arcadia and NobelClad divisions, as well as a constructive broader market backdrop.

investing.com2 min
OCT 28
$ULMed

Why is Unilever stock sliding today?

Unilever (ULVR) shares fell 3.0% to 4,744.5p after Q3 2026 results showed 5.2% sales growth, beating estimates but missing investor expectations due to volume deceleration. Turnover rose 6.7% to €13.3B. The Wellbeing division declined, and Foods saw minimal growth. UBS cut its target, while Bernstein maintained a Buy rating. The stock traded near session lows, down from 4,892.5p. The FTSE 100 was set to open lower.

investing.com2 min